(Q53631142)

16 May 2018

title

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. (English)

1 reference

16 May 2018

1 reference

1 reference

Juan Huang

1

1 reference

16 May 2018

Robert J Garmise

2

1 reference

16 May 2018

Timothy M Crowder

3

1 reference

16 May 2018

Kevin Mar

4

1 reference

16 May 2018

C Robin Hwang

5

1 reference

16 May 2018

Anthony J Hickey

6

1 reference

16 May 2018

John A Mikszta

7

1 reference

16 May 2018

Vincent J Sullivan

8

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 December 2004

1 reference

16 May 2018

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

16 May 2018

volume

23

1 reference

16 May 2018

page(s)

794-801

1 reference

16 May 2018

issue

6

1 reference

16 May 2018

Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Protection of cattle against rinderpest by intranasal immunisation with a dry powder tissue culture vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Dry powder inhalation as a potential delivery method for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Chitosan as a novel nasal delivery system for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

A powder formulation of measles vaccine for aerosol delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Immunity to infections on secretory surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Formation of secretory and circulating antibodies after immunization with live and inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Chitosan for mucosal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Protein powders for encapsulation: a comparison of spray-freeze drying and spray drying of darbepoetin alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

The impact of influenza epidemics on mortality: introducing a severity index.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Pandemic versus epidemic influenza mortality: a pattern of changing age distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Frequency and causes of vaccine wastage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Stabilization of proteins by low molecular weight multi-ions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Rational design of stable lyophilized protein formulations: theory and practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Absorption Enhancers for Nasal Drug Delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Chitosan as a novel nasal delivery system for peptide drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Clearance characteristics of chitosan based formulations in the sheep nasal cavity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Effect of chitosan on epithelial permeability and structure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.049

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.06.049

1 reference

16 May 2018

PubMed ID

15542204

1 reference

16 May 2018